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Background: Morphine-induced hyperalgesia and tolerance significantly limits its clinical use in relieving acute and
chronic pain. Melatonin, a pineal gland neurohormone, has been shown to participate in certain
neuropsychopharmacological actions. The present study investigated the effect of melatonin on morphine-induced
hyperalgesia and tolerance and possible involvement of protein kinase C (PKC)/N-methyl-D-aspartate (NMDA)
pathway in melatonin-mediated.
Methods: Experiments were performed on adult, male Sprague–Dawley rats. Melatonin (10 mg/kg, intraperitoneal,
i.p.) or saline was administrated 10 min after morphine injection (10 mg/kg, subcutaneous, s.c.) each day for
consecutive 14 days. Withdrawal threshold of the hindpaw to mechanical and thermal stimulation was measured
before any drug administration and one hour after melatonin or saline on each designated test day. On the 15th
day, thermal withdrawal was measured after s.c. morphine (20 mg/kg), but not melatonin, and morphine tolerance
was measured and expressed by MPAE% (percent of maximal possible anti-nociceptive effect) of morphine. Levels
of expression of protein kinase C gamma (PKCγ) and NMDA receptor subtype NR1 in spinal cord were detected by
Western blotting.
Results: The mechanical withdrawal threshold and thermal withdrawal latency decreased and shortened significantly
(i.e., threshold decreased) in rats that received morphine treatment for two weeks compared with that in rats receiving
saline. This morphine-induced mechanical and thermal hyperalgesia were greatly attenuated by co-administration of
morphine with melatonin. The MPAE% representing morphine analgesic effect was reduced approximately 60% in rats
that received morphine treatment. However, following the treatment of morphine with melatonin, the MPAE% was
reduced only about 30%, comparing with those that received saline treatment as control. Administration of morphine
alone resulted in significantly increased expression of PKCγ and NR1 proteins in the spinal cord. These increased levels
of expression of PKCγ and NR1 were significantly inhibited by co-administration of morphine with melatonin.
Conclusions: Our findings demonstrate that melatonin have potential to attenuate repetitive morphine-induced
hyperalgesia and tolerance, possibly by inhibiting PKCγ and NR1 activities in the spinal cord.
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Opioids such as morphine are effective analgesics that
are widely used in relieving acute and chronic pain [1].
However, repeatitive administration of morphine may
cause hyperalgesia [2,3], in addition to inducing anal-
gesic tolerance [4-7], a diminished morphine analgesic
effect. Morphine-induced hyperalgesia and analgesic
tolerance exhibit similar clinical manifestations, e.g., to
reach an adequate analgesic effect, it is necessary to
increase doses of morphine over time [3]. Therefore,
morphine-induced hyperalgesia and tolerance become a
real challenge that limits a lot of the clinical use of mor-
phine. In the past 20 years, many studies discussing
mechanisms of morphine-induced hyperalgesia and tol-
erance have been focusing on changes of neuronal plas-
ticity in the central nervous system (CNS) [6]. Such
neuronal plastic changes involve activation of excitatory
amino acid receptors, the subsequent intracellular cas-
cades including translocation and activation of PKC as
well as nitric oxide production, leading to the functional
modulation of receptor-ion channel complexes (e.g. the
desensitization of μ-opioid receptor) [4,5,7-16]. Studies
have shown that activations of PKC and NMDA receptor
in the spinal cord play critical roles in the develop-
ment of morphine-induced hyperalgesia and tolerance
[5,7,10,15,17]. Intrathecal co-administration of morphine
with GM1 ganglioside (a intracellular inhibitor of PKC
translocation) or chelerythrine chloride (a non-specific
PKC inhibitor) effectively attenuates the development of
the tolerance to morphine’s analgesic effect in rats
[4,10,15]. Likewise, intrathecal co-administration of mor-
phine with MK-801 (a non-competitive NMDA receptor
antagonist) or LY274614 (a competitive NMDA receptor
antagonist) also effectively prevents the development of
morphine tolerance in animals with or without nerve
injury [17,18]. Thus, inhibition of PKC and/or NMDA
receptor activities in the spinal cord may be able to ef-
fectively prevent the morphine-induced hyperalgesia and
tolerance.
Melatonin (N-acetyl-5-methoxytryptamine), a pineal
gland neurohormone synthesized from L-tryptophan,
has been demonstrated to play an important role in the
biologic regulation of circadian rhythms, sleep, mood,
reproduction, tumor growth, and neuroprotection [19-21].
Recent evidences have shown that systemic or intrathecal
administration of melatonin results in dose-dependent an-
algesic effect and prevents morphine-induced hyperalgesia
[3,22-25]. However, the cellular mechanisms underlying
such interaction of melatonin and morphine remain
elusive.
The present study was first to examine and confirm
the possible inhibitory effect of co-administration of
melatonin with morphine on morphine-induced hyper-
algesia and tolerance, then further to investigate thepossible role of PKCγ and NR1 activities in the spinal
cord in melatonin-induced reduction of morphine-
induced hyperalgesia and tolerance.
Methods
This study was conducted with the approval of the
Institutional Animal Experimental Ethics Committee of
Sichuan University (Chengdu, China). The experimental
protocol was approved by Institutional Animal Care and
Use committee of Sichuan University.
Experimental animals
Adult male Sprague–Dawley rats weighing 200 ± 50 g
(n = 24) provided by Sichuan University Medical Animal
Center (Chengdu, China) were used in this study. Rats
were housed in individual cages with free access to water
and food. Room temperature was maintained at 24°C
with a 12-hour light/darkness cycle. All experiments
were conducted during the period of 9 am to 4 pm on
each test day.
Drugs and treatments
Morphine hydrochloride (Shenyang First Pharmaceutical
Factory, Shen Yang, China) and melatonin (Sigma, St.
Louis, MO, US) were dissolved in saline.
Rats were randomly assigned to receive subcutaneous
(s.c.) administration of saline (1 ml/kg) or morphine
(10 mg/kg) or intraperitoneal (i.p.) saline or melatonin
(10 mg/kg). Melatonin or saline was administrated 10
min after morphine injection. Each regimen was given
once daily for consecutive 14 days. Based on our pre-
vious study, repetitive morphine treatment (10 mg/kg, s.c)
given once daily for 14 days can produce the tolerance to
morphine’s analgesic effect [15]. Moreover, according to
Raghavendra’s study, co-administration with morphine,
melatonin in dose of 10 mg/kg can significantly reverse
the morphine tolerance and dependent [26]. To avoid the
acute effect of melatonin on nociceptive response, on day
15 (24 h after the last treatment of consecutive 14 days
co-administration), all rats were injected with morphine
(20 mg/kg, s.c.) alone to further assess the tolerance to
morphine’s analgesic effect.
Behavioral assessments
Animals were habituated to the testing environment for
1 h each day for consecutive 3 days before the first be-
havioral test. Habituation consisted of moving rats from
their home room to the testing room and keeping them
in the testing apparatus for 1 h. The behavioral experi-
menters were blinded to the drug administration. Me-
chanical withdrawal threshold and thermal withdrawal
latency of all rats were measured on day 0 (before drug
administration), 1, 3, 5, 7 and 14. To avoid the acute ef-
fect of melatonin, morphine or the combination of
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nociceptive thresholds (mechanical withdrawal threshold
and thermal withdrawal latency) on both of the hindpaws
were determined before any drug administration on each
designated test day. The morphine tolerance was measured
at 60 min after co-administration (10 mg/kg melatonin
and/or 10 mg/kg morphine) from day 1 to 14, as well as at
60 min after administration of morphine (20 mg/kg) alone
on day 15. Rats were euthanized after the final behavioral
test and spinal cord samples were harvested.
Mechanical allodynia
Mechanical withdrawal threshold was measured using a
von Frey filament set with a calibrated range of bending
force (0.6, 1, 1.4, 2, 4, 6, 8, 10, 15, and 26 g) [27]. Each
rat was placed into a plastic cage with a wire mesh bot-
tom. A single filament was applied perpendicularly to
the plantar surface of the each hindpaw for five times
with an interval of 5 s. A positive response was defined
as at least one clear withdrawal response out of five ap-
plications. Filaments were applied in an up-and-down
order according to a negative or positive response to de-
termine the hindpaw withdrawal threshold.
Thermal hyperalgesia
Thermal withdrawal latency to radiant heat was deter-
mined according to a previously described method using
a 390 Analgesia Meter (IITC Inc., Woodland Hills, CA)
[28]. Rats were placed individually into plexiglas cubicles
placed on a transparent glass surface. The light beam
from a projection bulb, located below the glass, was di-
rected at the plantar surface of each hindpaw. Hindpaw
withdrawal latency was defined as the time from the on-
set of radiant heat stimulation to withdrawal of the hind-
paw. Radiant heat intensity was adjusted to result in a
baseline latency of about 12 s and a cut-off time of 20 s.
Three trials with an interval of 5 min were made for
each hindpaw and scores from three trials were averaged
to yield mean withdrawal latency for each hindpaw.
Morphine tolerance
Development of the tolerance to morphine’s analgesic ef-
fect was assessed by hindpaw thermal withdrawal latency
test [14,15]. The hindpaw thermal withdrawal latency
was converted to MPAE%. MPAE% was determined by
comparing the hindpaw withdrawal latency before (basal
latency) and after administration (test latency) using the
equation: MPAE% = [(test latency - basal latency)/
(20–basal latency) × 100% (20 s as the cut-off time). A
higher MPAE% represented a better analgesic effect.
Western blot
Rats in each experimental group (n = 3/6) were deeply
anesthetized with pentobarbital (80 mg/kg, i.p.) anddecapitated for rapid tissue harvesting. The L4-L5 seg-
ment of the spinal cord was first divided into the right
and left side and then further separated into the dorsal
and ventral horn, respectively. The tissues were dissected
and rapidly frozen on dry ice and stored at −80°C for
later Western blot analysis. Frozen tissue samples were
homogenized in a homogenization buffer (59 mM Tris–
HCl, 0.1mM EDTA, 0.1 mM EGTA, 1mM phenymethyl-
sulfonyl fluoride, 1 μM leupeptin, 2 μM pepstain A). The
homogenate was centrifuged at 4°C for 10 min at 8,000 × g.
The protein concentration of the supernatants was
assayed by using a microplate reader (Bio-TeK Instrument
Inc. Winooski, VT). Supernatants (50 μg) were heated for
10 min at 100°C and loaded onto 4% stacking/10% separ-
ating SDS-polyacrylamide gels for the protein separation.
The protein was then electrophoretically transferred
onto polyvinylidenedifluoride membrane (Millipore).
The membranes were then blocked with 5% non-fat dry
milk solution for 1 h and incubated overnight at 4°C
with a primary antibody (mouse anti-rabbit PKCγ,
1:100; 84 kDa or rabbit anti-mouse NR1, 1:500; 100
kDa) with moderate shaking. A corresponding horsera-
dish peroxidase -conjugated secondary antibody (Donkey
anti-rabbit or mouse, 1:5,000; Amersham Biosciences,
Arlington Heights, IL) and chemiluminescent solution
(NEN) were used to visualize a blot, followed by exposing
the blot onto hyperfilm (Amersham) for 5 min. Blots were
then incubated in a stripping buffer (67.5 mM Tris, pH
6.8, 2% SDS, and 0.7% b-mercaptoethanol) for 1 h at room
temperature and reprobed with a polyclonal rabbit anti-β-
actin antibody (1:10,000; Alpha Diagnostic International,
San Antonio, TX) as a loading control. Tissue samples
from experimental rats were probed in triplicate. The
density of each band was assayed with Adobe Photoshop
7.0 (Adobe Inc.) and normalized against each correspon-
ding β-actin loading control.
Immunohistochemistry
Rats in each experimental group (n = 3/6) were deeply
anesthetized with pentobarbital (80 mg/kg, i.p.) 24 h
after the last injection and transcardially perfused with
300 ml of 0.01M phosphate-buffered saline (PBS, pH
7.35) followed by 500 ml of 4% paraformaldehyde in
0.1 M phosphate buffer (PB, pH 7.35). Lumbar segments
of spinal cord (L4 and L5) were quickly removed and
post-fixed in the same fixative for overnight and cryo-
protected in 0.1M PB buffered 30% sucrose until the
segments sank to the bottom. Fixed tissues were pro-
cessed through graded alcohols and xylenes and
paraffin-embedded on the next day. Paraffin-embedded
tissue sections of 25 μm thickness were cut using a cryo-
stat and mounted onto slides. Sections were rinsed in
0.01 M PBS for 3 × 10 min. For fluorescence immuno-
staining of PKCγ and NR1, sections were blocked for
Figure 1 Melatonin attenuated morphine-induced mechanical
and thermal hyperalgesia. A: Hindpaw withdrawal threshold to
mechanical stimulation. B: Hindpaw withdrawal latency to thermal
stimulation. Mechanical withdrawal threshold and thermal withdrawal
latency were both gradually decreased and shortened, respectively, in
rats that received morphine (10 mg/kg, s.c.) alone from day 3 to 14.
Co-administration of morphine with melatonin(10 mg/kg, i.p.)
significantly prevented the decreased withdrawal threshold and
latency from day 3 to day 14. Six rats were included in each group.
*P < 0.05 and **P < 0.01, compared with SAL-SAL; # P <0.05 and
## P < 0.01, compared with MOR-SAL. Data are presented as
mean ± SEM.
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and 0.3% Triton X-100. After rinsing 3 × 10 min, sections
were incubated overnight at 4°C with a primary antibody
against PKCγ (1:100; mouse anti-rabbit polyclonal; Zymed
Laboratories Inc., South San Francisco, CA) or NR1
(1:250, rabbit anti-mouse monoclonal; Novus Biologicals,
Littleton, CO). After rinsing in PBS (3 × 10 min), the sec-
ondary antibody (1:500; CY3 or FITC conjugated donkey
anti-rabbit IgG, Jackson ImmunoResearch, West Grove,
PA) was added and sections were incubated for 2 h at
room temperature. These sections were again rinsed with
PBS and slip-covered. For double staining, the second pri-
mary antibody was added after incubation with the first
primary antibody following the same procedure. Six non-
adjacent sections were randomly selected and analyzed
using an Olympus fluorescence microscope, photographed
with a digital camera, and processed with Adobe Photo-
shop 7.0.
Statistical analysis
SPSS 16.0 (Chicago, IL) was used to conduct statistical
analysis . All data are expressed as mean ± SEM. The re-
petitive behavioral measurements were first tested for
normality and then tested by repeated-measures of
analysis of variance (Two-way ANOVA). MPAE% of mor-
phine as well as expression levels of PKCγ and NR1 were
analyzed by one-way ANOVA. All multiple-comparison
analyses were followed by post hoc Bonferroni’s cor-
rection. The statistical significance was set at a level of
P < 0.05.
Results
A total of twenty-four rats were included in the sta-
tistical analysis (n = 6 in each group). There were no
differences in baseline weight, mechanical withdrawal
threshold and thermal withdrawal latency among the
four groups in this study.
Melatonin attenuated morphine-induced hyperalgesia
Effects of melatonin on mechanical allodynia and ther-
mal hyperalgesia in rats are shown in Figure 1. The
hindpaw withdrawal threshold and latency of all rats
among four groups with different treatments showed no
significant difference on day 0 and 1 (P > 0.05). The
treatment with morphine (10 mg/kg, s.c.) and saline
(MOR-SAL) resulted in a progressive decreased with-
drawal threshold to mechanical stimulation and shortened
latency to heat stimulation during the post-injective 3–14
days. This is statistically significant compared with those
in groups of saline-saline (SAL-SAL) and saline- mela-
tonin (SAL-MT) (P < 0.001). Such increased mechanical
and thermal sensitivity of animals following repetitive
morphine treatment was greatly attenuated by co-
administration of morphine with melatonin (10 mg/kg,i.p.) in the group of morphine-melatonin (MOR-MT). The
treatment of saline or melatonin alone did not change the
sensitivity to the nociceptive stimulation.
Melatonin reduced morphine tolerance
Morphine tolerance and effects of melatonin on mor-
phine tolerance in inhibiting thermal hyperalgesia are
shown in Figure 2. Morphine (10 mg/kg, s.c.)-induced
analgesic effect on the thermal hypersensitivity was
Figure 2 Effect of melatonin on the morphine tolerance. The
development of the tolerance to morphine’s analgesic effect was
assessed by the hindpaw thermal withdrawal latency at 60 min after
co-administration (10 mg/kg melatonin and/or 10 mg/kg morphine)
from day 1 to 14 (A), as well as MPAE% of morphine at 60 min after
administration of morphine (20 mg/kg) alone on day 15 (B). A: Injection
of morphine (10 mg/kg) significantly increased the thermal withdrawal
latency in rats receiving administration of morphine on day 1.
However, such an analgesic effect gradually decreased and then
disappeared (tolerance) from day 3 to 14 after repeated treatment of
morphine. Co-administration of 10 mg/kg melatonin reversed the
analgesic effect of morphine. B: The MPAE% of morphine (20 mg/kg)
significantly decreased in rats receiving repeated administration of
morphine on day 15. However, the decreased MPAE% owing to
morphine tolerance was reversed by consecutive 14 days co-
administration of morphine with melatonin. MPAE% = [(test latency -
basal latency)/(20–basal latency) × 100% (20 s as the cut-off time).
*P < 0.05 and **P < 0.01, as compared with the SAL-SAL group at the
same time point; # P <0.05 and ## P < 0.01, as compared with the
MOR-SAL group at the same time point. Data are presented as
mean ± SD for 6 rats per group.
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treatment. Melatonin (10 mg/kg) treatment successfully
rescued the analgesic effect of morphine and such action
lasted for at least two weeks. Melatonin (10 mg/kg)
treatment at this dose alone did not significantly affect
the thermal hypersensitivity (Figure 2A). In Figure 2B,The MPAE% of morphine decreased about 60% in MOR-
SAL group, compared to the SAL-SAL group (P < 0.001),
on day 15. The decreased MPAE% owing to morphine
tolerance was reversed by consecutive 14 days co-
administration of morphine with melatonin. The MPAE%
in MOR-MT group was only decreased by about 30%
compared with SAL-SAL group, suggesting MPAE% was
significantly improved in rats of the MOR-MT group
(P = 0.001). MPAE% between groups of SAL-MT and
SAL-SAL was not significantly different (P > 0.05).
Melatonin inhibited the morphine-induced increased
expression of PKCγ and NR1 in the spinal cord
Western blot analysis showed that, following treatments
of morphine and/or melatonin for consecutive 14 days,
expressions of PKCγ and NR1 proteins were greatly in-
creased in MOR-SAL gourp, compared to the SAL-SAL
group(P > 0.05). The increased expression of PKCγ and
NR1 was significantly reduced by co-administration of
melatonin with morphine in the MOR-MT group, as
compared to that in the MOR-SAL group (P = 0.038;
P = 0.025) (Figure 3A and B). Melatonin treatment alone
caused alterations of expression of neither PKCγ nor
NR1. A co-localization of PKCγ and NR1 could be
detected by immunohistochemistry in superficial layers
(I and II) of the spinal cord dorsal horn in rats treated
with a combined morphine and melatonin for 14 con-
secutive days.
Discussion
The present study showed that morphine-induced hy-
peralgesia can be attenuated by co-administration of
morphine with melatonin over a 2-week period. More-
over, co-administration with melatonin also prevents a
2-week morphine treatment regimen-produced mor-
phine analgesic tolerance. The increased expression of
PKCγ and NR1 in the spinal cord of morphine exposed
rats is also inhibited by co-administration of morphine
with melatonin. These results indicate that melatonin
treatment can successfully alleviate morphine-induced
hyperalgesia and tolerance probably through inhibition
of PKCγ and NR1 activities in the spinal cord.
Morphine-induced hyperalgesia and tolerance are two
different phenomenons. Morphine-induced hyperalgesia
is a paradoxical increase in pain sensitivity that develops
after short- and/or long-term morphine exposure [2],
while morphine tolerance is a phenomenon in which re-
peated exposure to morphine results in decreased anal-
gesic effect of the drug or a need for a higher dose to
maintain the same analgesic effect, reflected in a right-
ward shift of the dose–response curve [2]. However,
morphine-induced hyperalgesia and tolerance exhibit
similar clinical manifestations, e.g., to reach an adequate
analgesic effect, it is necessary to increase doses of
Figure 3 Effects of melatonin on morphine-induced increased expression of PKCγ and NR1 in the spinal cord. Western blot shows
expression of PKCγ (A) and NR1 (B) in the spinal cord dorsal horn (n = 3) in each sample following treatment of morphine with or without
melatonin for consecutive 14 days. Data are presented as mean ± SEM. *P < 0.05, compared with SAL-SAL group # P < 0.05, compared with
MOR-SAL group. C: Co-localization of spinal PKCγ and NR1. There was co-localization of PKCγ and NR1 immunoreactivity in the superficial layers
(I and II) of the spinal cord dorsal horns at the lumbar (L4) level. Spinal cord samples were taken from rats receiving a combination of morphine
and melatonin for consecutive 14 days (n = 3). Blue: DAPI for nucleus. Scale bar: 100 μm. DL: the dorsolateral part of the spinal cord dorsal horn.
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thresholds and MPAE% of morphine in rats were pro-
gressively decreased by administration of morphine over
a 2-week period, demonstrating the development of
morphine-induced hyperalgesia and morphine tolerance.
Melatonin is a potent neuromodulator, and plays an
important role in physiologic and neuroendocrine func-
tions’ regulation via the high-affinity MT1 and MT2 re-
ceptors [23,29]. Studies have suggested an interactionbetween melatonin and opioids, i.e., melatonin can not
only enhance the analgesic effect of opioids, but also
reverse morphine-induced tolerance and dependence
[23,26,30]. Our study further confirmed these observa-
tions. In regards to morphine associated hyperalgesia,
melatonin can ameliorate the descending basic nocicep-
tive threshold in rats that received chronic treatment of
morphine, indicating that melatonin can prevent the de-
velopment of morphine-induced hyperalgesia. In regards
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tonin can attenuate the decreasing MPAE% of morphine
in rats that received chronic treatment of morphine, sug-
gesting melatonin can prevent the development of mor-
phine tolerance. it is noteworthy that, although in this
study melatonin attenuated morphine tolerance when
daily co-administered with morphine for 14 days, the
morphine analgesic effect was not affected in those rats
exposed only to melatonin when a single dose of mor-
phine was administrated only on day 15, suggesting that
repetitive, co-administration of melatonin with mor-
phine maybe necessary to demonstrate the impact of
melatonin on morphine anti-nociception. This observa-
tion is consistent with the previous reports [23,30,31].
Morphine-induced hyperalgesia and tolerance are
complex physiopathological conditions involving adapta-
tions at multiple levels in both CNS and in peripheral
tissues. Intracellular second messenger systems such as
PKC have been shown to modulate NMDA receptor ac-
tivation and play a critical role in molecular mechanisms
of morphine-induced hyperalgesia and morphine toler-
ance [5,10,15]. A series of studies suggest that μ-opioid
receptor activation induced by morphine treatment may
initiate G protein-mediated PKC translocation and acti-
vation, cause a removal of the Mg2+ blockade from the
NMDA receptor that allows for an increased influx of
Ca2+ [5]. Activation of PKC can modulate μ-opioid re-
ceptors responsiveness, resulting in desensitization of
the μ-opioid receptors [12]. Consistent with our previous
observation [15], in the present experiment, we have
demonstrated that expression of PKCγ and NR1, which
are co-localized within superficialI&II layers of the spinal
cord dorsal horn, were greatly increased in the dorsal
horn of rats that were exposed to morphine. We further
demonstrated that such increased expression of PKCγ
and NR1 was significantly inhibited by co-administration
of melatonin with morphine. These findings may sup-
port the idea that melatonin-induced alleviation of
morphine-induced hyperalgesia and tolerance is prob-
ably mediated through inhibition of the activity of PKC/
NMDA pathway. Besides, other possibilities such as acti-
vation of opioid system and benzodiazepine-GABAergic
pathway may be considered as well [25,26].
Taking together, our study support the possible mech-
anism underlying the effect of melatonin on morphine-
induced hyperalgesia and tolerance is probably through
inhibiting the prolonged activation of μ-opioid receptor-
induced PKCγ activity and the increased activity of NR1,
thus decreasing the influx of Ca2+, reducing the in-
creased neural excitability and gliocytes activity at the
spinal cord level. However, our current study does not
clarify how melatonin inhibits the PKC/NMDA pathway.
A possible mechanism is that melatonin decreases intra-
cellular cyclic adenosine monophosphate (cAMP) levelby inhibiting the activity of adenylate cyclase [3]. Data
we have provided in this study is limited, further studies
on regulation of PKC and NMDA receptors in melato-
nin’s modulation of morphine-induced hyperalgesia and
tolerance are urgently needed.
Conclusions
Our study suggests an idea that co-administration of
melatonin with morphine may be a helpful strategy for
enhancing the clinical use of morphine in treating
chronic pain and reducing the hyperalgesia and tole-
rance following repetitive morphine treatment .
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